Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials signals ...
CHAPEL HILL, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback